Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy

Metformin treatment was associated with a reduction in new-onset International Classification of Diseases (ICD) coding of geographic atrophy (GA), according to data presented at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Meeting.
In an interview with HCPLive, Dimitra Skondra, MD, PhD, an associate professor of ophthalmology and visual science and the director of the J. Terry Ernest Ocular Imaging Center at The University of Chicago, described the difficulties in controlling GA progression and the unmet need in targeting the disease before it gets to the advanced stages and vision loss.
“I think metformin fits very well, it’s almost the perfect candidate for a non-invasive strategy to target patients when they’re earlier in the disease stage,” Skondra told HCPLive. “It’s safe, affordable, and may help delay the process until they go to advantage stages of wet age-related macular degeneration (AMD) or GA in particular.”
Highlights
0:08 Knowledge of metformin, its potential benefit for retinal diseases
5:02 Protective effect of metformin in geographic atrophy
8:02 What does metformin offer for GA?
10:53 Next steps in research and implementation
Link to full article: www.hcplive.com/view/dimitra-...
More ARVO coverage: www.hcplive.com/conference/arvo
#retina #ophthalmology #conference